Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study

Serin, Ayfer; vatansever, sezgin

Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study

Ayfer SERİN, (Demiroğlu Bilim Üniversitesi)

Sezgin VATANSEVER (Atatürk Eğitim ve Araştırma Hastanesi)

Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi

1 1

Yıl: 2019 Cilt: 33 Sayı: 3 Sayfa Aralığı: 137 - 141 Metin Dili: İngilizce İndeks Tarihi: 19-04-2020

Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study

Öz:

Objective: Hepatitis B virus (HBV) infection is an important health problem in Turkey. Mortality and morbidity rates arise by accompanion of Hepatitis D infection (HDV). Prevalence of Hepatitis Delta virus (HDV) in HBV-positive individuals varies according to the regions in Turkey with 20% occurence in the western and up to 46% in the eastern parts. The aim of this study is to assess the presence of HDV in HBV patients applying to the center of our study. Materials and Methods: A total of 1025 patient records were reviewed retrospectively. Eighty-four were excluded due to insufficient case data; the remaining 941 patients were included in the review process. Patients were divided into those with chronic hepatitis B (group A) and those with liver cirrhosis (group B). HDV presence in both groups was assessed and compared between each group. Results: Of all 941 patients included in the study, 857 (91%) had chronic hepatitis B (Group A) and 84 (9%) had liver cirrhosis (Group B). Among group A patients, 62% were male and 38% were women; average age was 42±13 years. Group B patients were 77% male and 23% female; mean age was 54±14 years. Among all patients, HDV seropositivity was 3.4%, with 1.8% among group A patients and 20% in Group B (P= 0.001). Results were assessed by Chi-Square test and t–test. Group B patients were found to have significantly higher age (P= 0.007) and HDV seropositivity (P= 0.004) compared to group A patients. Conclusion: Cirrhotic patients were found to have 11-fold higher presence of HDV compared to non-cirrhotic patients.

Anahtar Kelime:

Konular: Cerrahi

Kronik Hepatit B Hastalarında Delta Hepatit Seroprevalansı: Tek Merkez Çalısması

Öz:

Amaç: Hepatit B virüs (HBV) infeksiyonu Türkiye’de önemli bir sağlık problemidir ve Hepatitis D infeksiyonu (HDV) ile birlikte olması ile mortalite ve morbidite artmaktadır. HDV prevelansı Türkiye’nin batı bölgesinde %20 iken Doğu Anadolu Bölgesinde %46 olarak farklılıklar göstermektedir. Bu çalışmanın amacı hastanemize gelen HBV hastalarındaki HDV seroprevalansı saptamaktır. Gereç ve Yöntem: Toplam 1025 hastanın kayıtları retrospektif olarak incelendi. 84 kişinin verileri yetersiz olduğundan dışlandı. Kalan 941 hastaya ait kayıtlar değerlendirildi. Hastalar Kronik Hepatit B (Group A) ve Siroz (Group B) olarak ayrıldı. Her iki grup arasında HDV infeksiyonunun bulunması açısından karşılaştırma yapıldı. Bulgular: 941 hastanın 857’si (%91) kronik Hepatit B (Grup A), 84’ü (%9) sirotik (Grup B) idi. Grup A daki hastların %62’si erkek, %38’i kadın olup yaş ortalaması 42±13 yıldı. Grup B deki hastaların %77’si erkek ve %23’ü bayan olup yaş ortalaması 54±14 yıldı. Grup B de yaş ortalaması daha yüksekdi (P= 0.015) Total hastalarda HDV seropozitifliği %3.4 olup, Grup A da %1.8, Grup B de %20 idi, Grup B de HDV pozitifliği yüksekti (P= 0.001). Sonuçlar ki kare ve t test ile değerlendirildi. Her iki grupta da erkek cinsiyet olması kadın cinsiyet olmasına göre daha yüksek oranda görüldü (Grup A da P= 0.007, Group B de P= 0.004) Sonuçlar istatistiksel olarak alamlı bulundu. Sonuç: Çalışmaya katılan tüm hastlarda %3.4 oranında HDV seropozitifliğ saptanmıştır. Sirotik hastlarda ise (%20), kronik hepatit B (%1.8) hastalarından 11 kattır.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rizzetto M, Canese MG, Arico J, et al. Immunofluorescence detection of a new antigen–antibody system associated to the hepatitis B virus in the liver and in the serum of HBsAg carriers. Gut 1977; 18: 997-1003.
2. Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated δ antigen to chimpanzees. J Infect Dis 1980; 141: 590-602.
3. Taylor JM, Farci P, Purcell RH. Hepatitis D (δ) virus. In: Knipe DM, (Editor). Fields Virology. PA, USA: Lippincott Williams & Wilkins, 2007: 3031-3046.
4. Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016; 64: S102–S116.
5. Jardi R, Buti M, Rodriguez-Frias F, et al. Clinical significance of two forms of IgM antibody to hepatitis delta virus. Hepatology 1991; 14: 24-28.
6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
7. Mansour W, Ducancelle A, Le Gal F, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010; 47: 97-99.
8. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-756
9. Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331.
10. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harbor perspectives in medicine 2015; 5: a021410.
11. Deny P. Hepatitis δ virus genetic variability: From genotypes I, II, III to eight major clades. Curr Top Microbiol Immunol 2006; 307: 151-171.
12. Hadler SC, Monzon M, Bensabath G. Epidemiology of hepatitis delta virus infection in less developed countries. Progr Clin Biol Res 1991; 364: 21-31.
13. Hadler SC, Fields HA. Hepatitis delta virus. In: Belshe RB (Editor). Textbook of human virology. 2nd Edition, St. Louis, London: The CV Mosby Co, 1991: 749-766.
14. Polish LB Gallagher M, Fields HA, Hadler SC. Delta hepatitis: Molecular biology and clinical and epidemiological features. Clin Microbiol Rev 1993; 6: 211229.
15. World Health Organization. “Hepatitis Delta”. http:// www.searo.who.int/EN/Section10/Section1027_9489.htm/ 05.06.2018.
16. Fonseca JC. Hepatitis D. Rev Soc Bras Med Trop 2002; 35: 181-190.
17. Uzun B, Şener AG, Güngör S, Afşar I, Demirci M. Evaluation of hepatitis delta virus (HDV) infection in blood donors in western Turkey. Transfüz Apher Sci 2014; 50: 388-391.
18. Moatter T, Abbas Z, Shabir S, Jafri W. Clinical presentation and genotype of hepatitis delta in Karachi. World J Gastroenterol 2007; 13: 2604-2607.
19. Smedile AC, Lavarini P, Farci S, et al. Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. Am J Epidemiol 1993; 117: 223-229.
20. Maynard JE, Hadler SC, Fields HF. Delta hepatitis in the Americas: An overview. Prog Clin Biol Res 1987; 234: 493-505.
21. Berberian H, Dodd RY. Antibodies to delta antigen in asymptomatic hepatitis B surface antigen-reactive blood donors in the United States and their association with other markers of hepatitis B virus. Am J Epidemiol 1985; 122: 218-225.
22. Yurdaydin C. Delta hepatitis in Turkey: Decreasing but not vanishing and still of concern. Turk J Gastroenterol 2006; 17: 74-75.
23. Değertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: A meta-analysis. Liver Int 2008; 28: 494-498.
24. Gupta P, Biswas D, Shukla I, Bal A. Need for routine screening of HBV and HDV in patients with cirrhosis of the liver. Ind J Med Microbiol 2005; 23: 141-142.
25. Carmo-Fonseca JC. Hepatitis D. Rev Soc Bras Med Trop 2002; 35: 181-190.
26. Rizzetto M, Hoyer B, Canese MG, Pureell RH, Gerin JL. Delta agent association of Delta antigen with hepatitis B surface antigen and RNA in serum of Delta infected chimpanzees. Proc Natt Acad 1989; 77: 6124-6128.
27. Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc 2006; 105: 869-881.
28. Türkdoğan MK, Bozkurt H, Uygan I, ve ark. Chronic hepatitis delta virus infection in Van region of eastern Turkey. Turk J Gastroenterol 2005; 16: 17-20.
29. Degertekin H, Yalcın K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: An analysis of clinical studies. Turk J Gastroenterol 2006; 17: 25-34.
30. Kose Ş, Ece G, Gozaydin A, Turken M. Hepatitis delta in western Turkey. J Infect Dev Ctries 2012; 6: 782-785.
31. Dulger AC, Suvak B, Gonullu H, ve ark. High prevalence of chronic hepatitis D virus infection in Eastern Turkey: urbanization of the disease, Arch Med Sci 2016; 12: 415420.
32. Sanou AM, Benkirane K, Tinto B, et al. Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. Int J Infect Dis 2018; 70: 15-19.
33. Rizetto M. Chronic Hepatitis D. At a Standstill? Dig Dis 2016; 34: 303-307.
34. Akarsu M, Akıncı EG, Akkız H, ve ark. Diagnosis, management and treatment of hepatitis delta virus infection.Turk J Gastroenterol 2017; 28: 84-89.

APA	Serin A, vatansever s (2019). Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. , 137 - 141.
Chicago	Serin Ayfer,vatansever sezgin Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. (2019): 137 - 141.
MLA	Serin Ayfer,vatansever sezgin Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. , 2019, ss.137 - 141.
AMA	Serin A,vatansever s Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. . 2019; 137 - 141.
Vancouver	Serin A,vatansever s Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. . 2019; 137 - 141.
IEEE	Serin A,vatansever s "Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study." , ss.137 - 141, 2019.
ISNAD	Serin, Ayfer - vatansever, sezgin. "Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study". (2019), 137-141.

APA	Serin A, vatansever s (2019). Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, 33(3), 137 - 141.
Chicago	Serin Ayfer,vatansever sezgin Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi 33, no.3 (2019): 137 - 141.
MLA	Serin Ayfer,vatansever sezgin Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, vol.33, no.3, 2019, ss.137 - 141.
AMA	Serin A,vatansever s Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi. 2019; 33(3): 137 - 141.
Vancouver	Serin A,vatansever s Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi. 2019; 33(3): 137 - 141.
IEEE	Serin A,vatansever s "Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study." Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, 33, ss.137 - 141, 2019.
ISNAD	Serin, Ayfer - vatansever, sezgin. "Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study". Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi 33/3 (2019), 137-141.